Infla-650 Herbal Dietary Supplement Capsules

No lo uses. Devuélvelo a la tienda o bótalo. Si te sentiste mal después de usarlo, llama a tu médico y dile qué tomaste.

El aviso no da tamaños, fechas ni lotes. Compara la marca y el producto con el aviso oficial.

Guru Inc. retiró este producto. Motivo: Contiene un medicamento no aprobado.

Risk Statement: Use of the product poses a serious threat to consumers because it may result in unintentional acetaminophen overdose, especially if it is used in combination with other acetaminophen-containing products. Acetaminophen overdose can cause liver damage (hepatoxicity), ranging in severity from abnormalities in liver function to acute liver failure, and even death. People who experience unintentional acetaminophen overdose may not seek prompt medical attention because the symptoms of liver damage can take several days to emerge, even in severe cases. Acetaminophen may also cause serious skin reactions. Symptoms may include skin reddening, rash, and blisters.

Tiene un medicamento que no aparece en la etiqueta. Puede ser peligroso, sobre todo si tomas otras medicinas.

En todo EE. UU. (distribución nacional). El aviso no nombra Puerto Rico, pero pudo haber llegado aquí.

Según el aviso: Consumers and retailers that have Infla-650 which is being recalled should stop using/return to place of purchase. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online,…

FDA recall announcement: GURU INC. Issues Voluntary Nationwide Recall of Infla-650 Herbal Dietary Supplement Capsules Due to Hidden Drug Ingredients Company: Guru Inc. Product: Infla-650 Herbal Dietary Supplement Capsules (brand: Infla-650) Reason: Tainted with the drug ingredients: acetaminophen, diclofenac and phenylbutazone [Unapproved Drug] Distribution: Consumers and retailers that have Infla-650 which is being recalled should stop using/return to place of purchase. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by